First Warning System (Breast Cancer Detection)

It is estimated that over one million American women have breast cancer right now and do not know it. Many health authorities favor attempting to distinguish women who are likely to develop breast cancer, based on varying elements of risk, from those who are not. The flaw in any risk-based approach to screening for breast cancer becomes apparent if one considers that as many as 60%-70% of all breast cancer patients have no obvious risk factor. Simply stated, the available screening programs, despite being directed toward finding early stage disease, do not adequately warn women or their physicians that breast cancer is present in its earliest or preclinically detectable stages.

Over 30 million mammograms will be done this year; of this group, 1.1 million women will be subjected to breast biopsies. From these biopsies, 185,000 new breast cancer cases will be found. Unfortunately, another 915,000 or 83% of women will be told their biopsies were benign. The accurate detection of pre-cancerous lesions is the key to making a major step forward in the eradication of this disease.

Progression of Angionesis
Day 1	Day 7	Day 14

Lifeline Biotechnologies^TM is developing a non-imaging technology called First Warning™ that measures tissue activity. The technological concept behind First Warning™ is that new blood vessels supplying a breast cancer do not respond to normal physiological control mechanisms (vasoconstriction and vasodilatation). Therefore, cancers produce time-related circadian (24 hour) pattern change not seen in normal tissue. It is proposed these changes in the circadian rhythm "chaos" is taken as a signal of high risk for breast cancer even in the absence of mammographic evidence.

View Tumor Growth Process

First Warning™ is a dynamic test (like a motion picture) collecting information over time, unlike traditional imaging systems, which are static providing a snapshot of information at the time of the test. The monitor records information every 5 minutes for the duration of the test, collecting over 9,000 data points. The data is then subjected to non-linear algorithmic computer analysis designed to identify abnormalities or disruptions in the normal breast physiology.

top